Target |
Mechanism DNA inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date20 Mar 2008 |
Target |
Mechanism Proteasome inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date13 May 2003 |
Target |
Mechanism CD20 inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date26 Nov 1997 |
Start Date12 Oct 2017 |
Sponsor / Collaborator |
Start Date29 Jul 2016 |
Sponsor / Collaborator |
Start Date01 Sep 2015 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Cyclophosphamide ( DNA ) | Chronic Lymphocytic Leukemia More | Pending |
Bendamustine Hydrochloride ( DNA ) | Recurrent Follicular Lymphoma More | Pending |
Rituximab ( CD20 ) | Mantle-Cell Lymphoma More | Pending |
Fludarabine Phosphate ( DNA polymerase III x RNA polymerase II x Ribonucleotide reductase ) | Chronic Lymphocytic Leukemia More | Pending |
Dexamethasone ( GR ) | Multiple Myeloma More | Pending |